Craft

Bluebird Bio

Stock Price

$3.4

2023-08-22

Market Capitalization

$365.8 M

2023-08-22

Revenue

$3.6 M

FY, 2022

Bluebird Bio Summary

Company Summary

Overview
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer. The company works on programs in severe genetic diseases that include betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia); LentiGlobin gene therapy for sickle cell disease, or SCD; and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy, or CALD). Its programs in oncology are focused on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.
Type
Public
Status
Active
Founded
1992
HQ
Cambridge, MA, US | view all locations
Website
https://www.bluebirdbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Nick Leschly
  • Melissa Bonner

    Melissa Bonner, Senior Vice President, Research

  • Sarah Alspach

    Sarah Alspach, SVP, External Affairs

    • Kasra Kasraian

      Kasra Kasraian, Senior Vice President, Technical Development and Operations

      Operating MetricsView all

      Patents and Patent Applications

      1.2K
      4.1%

      FY, 2020

      LocationsView all

      10 locations detected

      • Cambridge, MA HQ

        United States

        60 Binney St

      • Durham, NC

        United States

        1733 TW Alexander Dr

      • Seattle, WA

        United States

        188 E Blaine St #300

      • Paris, IDF

        France

        75 Boulevard Haussmann

      • München, BY

        Germany

        Josephspitalstraße 15

      • Athens

        Greece

        166A, Kifissias Avenue & 2 Sofokleous Str. GR-151 26 Maroussi

      and 4 others

      Bluebird Bio Financials

      Summary Financials

      Revenue (Q2, 2023)
      $6.9M
      Gross profit (Q2, 2023)
      ($2.7M)
      Net income (Q2, 2023)
      ($72.9M)
      Cash (Q2, 2023)
      $172.9M
      EBIT (Q2, 2023)
      ($85.3M)
      Enterprise value
      $499.8M

      Footer menu